Marc R Dweck1, Anda Bularga1, Rebecca T Hahn2, Rong Bing1, Kuan Ken Lee1, Andrew R Chapman1, Audrey White1, Giovanni Di Salvo3, Leyla Elif Sade4, Keith Pearce5, David E Newby1, Bogdan A Popescu6, Erwan Donal7, Bernard Cosyns8, Thor Edvardsen9,10, Nicholas L Mills1,11, Kristina Haugaa9,10. 1. Centre for Cardiovascular Science, University of Edinburgh, UK. 2. Columbia University Irving Medical Center, NY, USA. 3. University Hospital Padua, Paediatric Cardiology, Padua, Italy. 4. Department of Cardiology, University of Baskent, Ankara, Turkey. 5. University Hospital South Manchester, Cardiology, Wythenshawe, Manchester, UK. 6. Department of Cardiology, University of Medicine and Pharmacy 'Carol Davila'-Euroecolab, Emergency Institute for Cardiovascular Diseases 'Prof. Dr. C. C. Iliescu', Bucharest, Romania. 7. University of Rennes, CHU Rennes, Inserm, LTSI-UMR 1099, Rennes, France. 8. Centrum voor Hart en Vaatziekten, Universitair Ziekenhuis Brussel, Vrij Universiteit van Brussel, Brussels, Belgium. 9. Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway. 10. Faculty of Medicine, University of Oslo, Oslo, Norway. 11. Usher Institute, University of Edinburgh, UK.
Abstract
AIMS: To describe the cardiac abnormalities in patients with COVID-19 and identify the characteristics of patients who would benefit most from echocardiography. METHODS AND RESULTS: In a prospective international survey, we captured echocardiography findings in patients with presumed or confirmed COVID-19 between 3 and 20 April 2020. Patient characteristics, indications, findings, and impact of echocardiography on management were recorded. Multivariable logistic regression identified predictors of echocardiographic abnormalities. A total of 1216 patients [62 (52-71) years, 70% male] from 69 countries across six continents were included. Overall, 667 (55%) patients had an abnormal echocardiogram. Left and right ventricular abnormalities were reported in 479 (39%) and 397 (33%) patients, respectively, with evidence of new myocardial infarction in 36 (3%), myocarditis in 35 (3%), and takotsubo cardiomyopathy in 19 (2%). Severe cardiac disease (severe ventricular dysfunction or tamponade) was observed in 182 (15%) patients. In those without pre-existing cardiac disease (n = 901), the echocardiogram was abnormal in 46%, and 13% had severe disease. Independent predictors of left and right ventricular abnormalities were distinct, including elevated natriuretic peptides [adjusted odds ratio (OR) 2.96, 95% confidence interval (CI) 1.75-5.05) and cardiac troponin (OR 1.69, 95% CI 1.13-2.53) for the former, and severity of COVID-19 symptoms (OR 3.19, 95% CI 1.73-6.10) for the latter. Echocardiography changed management in 33% of patients. CONCLUSION: In this global survey, cardiac abnormalities were observed in half of all COVID-19 patients undergoing echocardiography. Abnormalities were often unheralded or severe, and imaging changed management in one-third of patients.
AIMS: To describe the cardiac abnormalities in patients with COVID-19 and identify the characteristics of patients who would benefit most from echocardiography. METHODS AND RESULTS: In a prospective international survey, we captured echocardiography findings in patients with presumed or confirmed COVID-19 between 3 and 20 April 2020. Patient characteristics, indications, findings, and impact of echocardiography on management were recorded. Multivariable logistic regression identified predictors of echocardiographic abnormalities. A total of 1216 patients [62 (52-71) years, 70% male] from 69 countries across six continents were included. Overall, 667 (55%) patients had an abnormal echocardiogram. Left and right ventricular abnormalities were reported in 479 (39%) and 397 (33%) patients, respectively, with evidence of new myocardial infarction in 36 (3%), myocarditis in 35 (3%), and takotsubo cardiomyopathy in 19 (2%). Severe cardiac disease (severe ventricular dysfunction or tamponade) was observed in 182 (15%) patients. In those without pre-existing cardiac disease (n = 901), the echocardiogram was abnormal in 46%, and 13% had severe disease. Independent predictors of left and right ventricular abnormalities were distinct, including elevated natriuretic peptides [adjusted odds ratio (OR) 2.96, 95% confidence interval (CI) 1.75-5.05) and cardiac troponin (OR 1.69, 95% CI 1.13-2.53) for the former, and severity of COVID-19 symptoms (OR 3.19, 95% CI 1.73-6.10) for the latter. Echocardiography changed management in 33% of patients. CONCLUSION: In this global survey, cardiac abnormalities were observed in half of all COVID-19 patients undergoing echocardiography. Abnormalities were often unheralded or severe, and imaging changed management in one-third of patients.
Authors: Mohammad Madjid; Allison T Connolly; Yelena Nabutovsky; Payam Safavi-Naeini; Mehdi Razavi; Charles C Miller Journal: Am J Cardiol Date: 2019-04-10 Impact factor: 2.778
Authors: Mohammad Madjid; Charles C Miller; Vladimir V Zarubaev; Ivan G Marinich; Oleg I Kiselev; Yury V Lobzin; Alexander E Filippov; Samuel Ward Casscells Journal: Eur Heart J Date: 2007-04-17 Impact factor: 29.983
Authors: Mehrdad Saririan; Richard Armstrong; Jon C George; Bartosz Olechowski; Stephen O'Connor; James Brian Byrd; Andrew R Chapman Journal: Eur Heart J Case Rep Date: 2021-02-08
Authors: Jason Roh; Robert Kitchen; J Sawalla Guseh; Jenna McNeill; Malika Aid; Amanda Martinot; Andy Yu; Colin Platt; James Rhee; Brittany Weber; Lena Trager; Margaret Hastings; Sarah Ducat; Peng Xia; Claire Castro; Bjarni Atlason; Timothy Churchill; Marcelo Di Carli; Patrick Ellinor; Dan Barouch; Jennifer Ho; Anthony Rosenzweig Journal: Res Sq Date: 2021-06-08
Authors: Greg Vanichkachorn; Richard Newcomb; Clayton T Cowl; M Hassan Murad; Laura Breeher; Sara Miller; Michael Trenary; Daniel Neveau; Steven Higgins Journal: Mayo Clin Proc Date: 2021-05-11 Impact factor: 7.616